{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-007529","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.623753+00:00","generated_at":"2026-05-27T08:33:34.158843+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"60 Degrees Pharma announces IRB approval for Phase II study of tafenoquine in chronic babesiosis","bullets":["IRB-approved open-label Phase II study (NCT06656351) evaluating tafenoquine for chronic babesiosis.","Patient enrollment expected to begin in Q3 2025; participants must have >6 months functional impairment.","Company estimates cumulative addressable market of >400,000 patients through end of U.S. patent protection in 2035.","No approved treatment currently exists for chronic babesiosis."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-007529","json":"https://secwatch.observer/filing/0001213900-25-007529.json","markdown":"https://secwatch.observer/filing/0001213900-25-007529.md","text":"https://secwatch.observer/filing/0001213900-25-007529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025007529/0001213900-25-007529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390025007529/ea0228966-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:33:34.158843+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}